Agenda Available Online
NEW YORK, NY – September 13, 2016 – The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.
Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease. The studies selected will examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Sunday, October 30; Monday, October 31; Tuesday, November 1; and Wednesday, November 2. TCT press conferences will be held each morning beginning at 7:30 AM ET.
The complete agenda for TCT 2016 is now available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT. To apply for media credentials, visit: http://www.crf.org/tct/press/press-registration-form.
Sunday, October 30
Late-Breaking Trials
ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease
Ziad A. Ali
BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery Disease
Clemens von Birgelen
BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery Disease
David E. Kandzari
First Report Investigations
ABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease
Runlin Gao
ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease
Patrick W. Serruys
LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding Risk
Philip M. Urban
Monday, October 31
Late-Breaking Trials
EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease
Gregg W. Stone
NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease
Evald H. Christiansen
First Report Investigations
REVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled Stent
Stephen G. Worthley
FANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease
Alexandre Abizaid
MeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease
Ashok Seth
FORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease
Antonio Colombo
FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease
Bo Xu
Tuesday, November 1
Late-Breaking Trials
SENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Susheel Kodali
PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate Risk Patients with Severe Aortic Stenosis
David J. Cohen
PARTNER I FIVE-YEAR ECHO: Long-Term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Aortic Stenosis
Pamela S. Douglas
First Report Investigations
RESPECT: Final Long-Term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke
David E. Thaler
COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes after Stent Implantation in Patients with Coronary Artery Disease
Giora Weisz
PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and Minorities
Wayne B. Batchelor
ReACT: A Prospective, Randomized Trial of Routine Angiographic Follow-up After Coronary Artery Stent Implantation
Hiroki Shiomi
Wednesday, November 2
Late-Breaking Trials
ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries
Sean P. Lyden
WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation
Vivek Y. Reddy
AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation
David Hildick-Smith
First Report Investigations
PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients with Coronary Artery Chronic Total Occlusions
Koen Teeuwen
TOSCA-5: A Prospective, Randomized Trial Evaluating Collagenase Infusion in Patients with Coronary Artery Chronic Total Occlusions
Christopher E. Buller
TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at 3 Months and Neoatherosclerosis at 18 Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents
Giulio Guagliumi
RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis – 6-9 Month Clinical and Angiographic Follow-up Results
Fernando Alfonso
Receive updates on Twitter at http://twitter.com/TCTConference and https://twitter.com/crfheart.